טוען...
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
Guidelines for the treatment of non-small cell lung cancer adenocarcinoma positive in epidermal growth factor mutations indicate tyrosine kinase inhibitors. There are currently three tyrosine kinase inhibitors that can be used as first line treatment: gefitinib, erlotinib and afatinib. Regarding erl...
שמור ב:
| הוצא לאור ב: | Respir Med Case Rep |
|---|---|
| Main Authors: | , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5458763/ https://ncbi.nlm.nih.gov/pubmed/28616379 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.05.013 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|